We are live on ! Find out more
KBIO

KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO

Delisted

KBIO was delisted on the 16th of December, 2015.

48 hedge funds and large institutions have $52.2M invested in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in 2014 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 12

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

4% more funds holding

Funds holding: 4648 (+2)

41% less capital invested

Capital invested by funds: $89.1M → $52.2M (-$36.9M)

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
48
Holders Change
+2
Holders Change %
+4.35%
% of All Funds
1.39%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
11
Increased
20
Reduced
12
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
TC
26
TFS Capital
Pennsylvania
$146K +$196K +6,757 New
NFA
27
Nationwide Fund Advisors
Ohio
$117K +$126K +4,340 +408%
PPA
28
Parametric Portfolio Associates
Washington
$116K +$155K +5,347 New
BIM
29
BlackRock Investment Management
Delaware
$98K +$18.4K +634 +16%
Credit Agricole
30
Credit Agricole
France
$96K -$10.1K -350 -7%
Renaissance Technologies
31
Renaissance Technologies
New York
$79K +$38.8K +1,339 +58%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$76K +$15.9K +550 +19%
Jane Street
33
Jane Street
New York
$72K +$96.9K +3,344 New
Charles Schwab
34
Charles Schwab
California
$64K
TCIM
35
TIAA CREF Investment Management
New York
$63K
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$58K
ARTA
37
A.R.T. Advisors
New York
$42K +$56.4K +1,946 New
Barclays
38
Barclays
United Kingdom
$41K +$7.65K +264 +11%
CS
39
Credit Suisse
Switzerland
$36K -$14.7K -506 -23%
ProShare Advisors
40
ProShare Advisors
Maryland
$33K +$43.6K +1,506 New
GC
41
Guggenheim Capital
Illinois
$33K +$44.1K +1,523 New
BA
42
BlackRock Advisors
Delaware
$23K +$5.85K +202 +24%
AIG
43
American International Group
New York
$21.9K +$695 +24 +2%
TA
44
Teachers Advisors
New York
$20K
Citigroup
45
Citigroup
New York
$5K -$9.88K -341 -60%
TRCT
46
Tower Research Capital (TRC)
New York
$1K +$898 +31 New
MAM
47
MPM Asset Management
Massachusetts
-$11.6M -329,116 Closed
LBH
48
Lehman Brothers Holdings
New York
-$2.91M -82,180 Closed
Franklin Resources
49
Franklin Resources
California
-$2.74M -77,443 Closed
Principal Financial Group
50
Principal Financial Group
Iowa
-$2.34M -66,214 Closed

KBIO Hedge Fund Activity: Q1 2014 in Review

48 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) for Q1 2014, worth a combined $52.2M — down 41% from $89.1M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new KBIO positions and 9 closed out — a net gain of 2 holders — while 20 added to existing stakes and 12 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $10.1M. The largest seller was MPM Asset Management, exiting entirely with an estimated $11.6M sold.

  • 48 institutional investors held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) as of Q1 2014, up from 46 in Q4 2013.
  • Funds reported $52.2M of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) stock for Q1 2014, down 41% quarter-over-quarter.
  • 11 funds opened new KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) positions in Q1 2014 and 9 closed out, a net change of +2 holders.
  • The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) buyer in Q1 2014 was Deerfield Management, an estimated $10.1M added.
  • The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) seller in Q1 2014 was MPM Asset Management, an estimated $11.6M sold.

Based on aggregated 13F filings for Q1 2014.